Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Eli Lilly Looks To Positive Data To Expand Its Market Opportunity For Emgality [Seeking Alpha]

Alder BioPharmaceuticals, Inc (ALDR)  More Company Research Source: Seeking Alpha
Last alder biopharmaceuticals, inc earnings: 8/6 04:07 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.alderbio.com/node/5806
PDF Eli Lilly Looks To Positive Data To Expand Its Market Opportunity For Emgality Summary Eli Lilly announced that it had achieved a positive outcome in its phase 3 study in that the primary endpoint was met with statistical significance. It was shown that Emgality was able to reduce monthly migraine headache days by about 4.1 days, compared to placebo with only 1.0 day. Sales for Emgality in Q2 of 2019 reached $33.8 million. Competition is fierce in the CGRP space with several other companies in place like Amgen and Novartis, Teva, and soon to possibly be Alder BioPharmaceuticals. LLY Phase 3 Data Provides Solid New Option For Patients The phase 3 trial was known as CONQUER. This late-stage study recruited patients with chronic and episodic migraines. Emgality was given to these patients to act as a preventative treatment for them. However, one thing to note is that this was a population of patients who had failed on two or four prior standard-of-care (SOC) treatments. Why would these p [Read more]
Impact snapshot Event time: ALDR
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
ALDR alerts
from News Quantified
Opt-in for
ALDR alerts

from News Quantified
Opt-in for
ALDR alerts

from News Quantified